Jump in at the deep end December 2015 With her Master’s in Biochemistry still warm in her hand, market analyses, pricing strategies and product launches were already waiting for her. Gabriela Güntherodt, at that time a…

The company NextImmune , founded at the Biozentrum of the University of Basel in 2021, focuses on the development of selective immunosuppressive therapy. This novel class of drugs specifically suppresses the immune system…

No Plan B! December 2015 Throwing in the towel has never crossed his mind, despite some severe setbacks. A failure is not the end of the world. And so Santhera CEO Thomas Meier has never had a plan B tucked away at the back…

The BaseLaunch program was launched in 2017 as an initiative of BaselArea.swiss, the office for business promotion for Northwestern Switzerland, with the aim of strengthening the start-up scene in the Basel region and…

Technology Ventures The primary goal of the basic research investigations in molecular and biomedical biology at the Biozentrum is to investigate central questions about the smallest unit of life, the cell, as well as vital…

The Biozentrum startup Translation-X is pioneering a precision medicine approach to address the core symptoms of autism-spectrum disorders such as social interaction difficulties. The company recently reached an important…

T3 Pharmaceuticals is one of top five startup companies selected by the W.A. de Vigier Foundation. The winning companies were selected from a record number of 256 applications in a multi-step process. At the award ceremony…

Always on duty for the environment December 2018 Springtails, earthworms, midges, zebrafish, bees and bacteria – they all have an important job at Innovative Environmental Services (IES) Ltd. With their help, the company can…

T3 Pharmaceuticals (“T3 Pharma”) was founded in 2015 as a spin-off of the Biozentrum of the University of Basel. The company focuses on bacterial therapies for the treatment of solid tumors. The Basel-based biotech company’s…

“The closure of this financing round and the successful recruitment of 545 patients in our first clinical study at the University Hospital Basel this year is a huge success”, states Marija Plodinec, CEO of ARTIDIS. “We are…